Valganciclovir is not associated with decreased EBV infection rate in pediatric kidney transplantation

• Main Authors: Elodie Cheyssac (Author), Hamidou Savadogo (Author), Nathan Lagoutte (Author), Véronique Baudouin (Author), Marina Charbit (Author), Robert Novo (Author), Anne-Laure S (Author), Marc Fila (Author), Stéphane Decramer (Author), Elodie Merieau (Author), Ariane Zaloszyc (Author), Jérôme Harambat (Author), Gwenaelle Roussey (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

IntroductionPrimary infection or reactivation of Epstein-Barr Virus (EBV) is a significant cause of morbidity and mortality in pediatric kidney transplantation. Valganciclovir (VGC) treatment is recommended for prophylaxis of cytomegalovirus infection, but its role for the prevention of EBV infectio...